Discovery of new potent molecular entities able to inhibit mPGES-1

European Journal of Medicinal Chemistry

Volumn 143, Issue , 2018, Pages 1419-1427

  Di Micco, Simone ^a   Terracciano, Stefania ^a   Cantone, Vincenza ^a,b   Fischer, Katrin ^b   Koeberle, Andreas ^b   Foglia, Antonio ^a   Riccio, Raffaele ^a   Werz, Oliver ^b   Bruno, Ines ^a   Bifulco, Giuseppe ^a  

^a UNIVERSITY OF SALERNO   (Italy)

^b FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

Author keywords

Anti inflammatory drugs; In silico screening; mPGES 1; mPGES 1 inhibitors; Suzuki Miyaura cross coupling

Indexed keywords

1 FLUORO 2,4 DINITRO BIPHENYL DERIVATIVE; BIPHENYL DERIVATIVE; MEMBRANE PROTEIN; MPGES 1 PROTEIN; PROSTAGLANDIN INHIBITOR; PROSTAGLANDIN SYNTHASE; UNCLASSIFIED DRUG; ENZYME INHIBITOR; PROSTAGLANDIN E SYNTHASE; PTGES PROTEIN, HUMAN;

ARTICLE; CONTROLLED STUDY; DRUG DETERMINATION; DRUG IDENTIFICATION; DRUG POTENCY; DRUG SCREENING; DRUG SYNTHESIS; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; IC50; MOLECULAR DOCKING; SUZUKI REACTION; ANTAGONISTS AND INHIBITORS; CHEMISTRY; DRUG DEVELOPMENT; METABOLISM; PROTEIN CONFORMATION; SYNTHESIS;

DRUG DISCOVERY; ENZYME INHIBITORS; HUMANS; MOLECULAR DOCKING SIMULATION; PROSTAGLANDIN-E SYNTHASES; PROTEIN CONFORMATION;

EID: 85033582141     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2017.10.039     Document Type: Article

References (42)

1. Maione, F., Cantone, V., Pace, S., Chini, M.G., Bisio, A., Romussi, G., Pieretti, S., Werz, O., Koeberle, A., Mascolo, N., Bifulco, G., Anti-inflammatory and analgesic activity of carnosol and carnosic acid in vivo and in vitro and in silico analysis of their target interactions. Br. J. Pharmacol. 174 (2017), 1497–1508.
2. Koeberle, A., Laufer, S.A., Werz, O., Design and development of microsomal prostaglandin E2 synthase-1 inhibitors: challenges and future directions. J. Med. Chem. 59:13 (2016), 5970–5986.
3. Li, D., Howe, N., Dukkipati, A., Shah, S.T., Bax, B.D., Edge, C., Bridges, A., Hardwicke, P., Singh, O.M., Giblin, G., Pautsch, A., Pfau, R., Schnapp, G., Wang, M., Olieric, V., Caffrey, M., Crystallizing membrane proteins in the lipidic mesophase. Experience with human prostaglandin E2 synthase 1 and an evolving strategy. Cryst. Growth Des. 14 (2014), 2034–2047.
4. Côté, B., Boulet, L., Brideau, C., Claveau, D., Ethier, D., Frenette, R., Gagnon, M., Giroux, A., Guay, J., Guiral, S., Mancini, J., Martins, E., Massé, F., Méthot, N., Riendeau, D., Rubin, J., Xu, D., Yu, H., Ducharme, Y., Friesen, R.W., Substituted phenanthrene imidazoles as potent, selective, and orally active mPGES-1 inhibitors. Bioorg. Med. Chem. Lett. 17 (2007), 6816–6820.
5. Sjçgren, T., Nord, J., Ek, M., Johansson, P., Liu, G., Geschwindner, S., Crystal structure of microsomal prostaglandin E2 synthase provides insight into diversity in the mapeg superfamily. Proc. Natl. Acad. Sci. U. S. A. 110 (2013), 3806–3811.
6. Miyaura, N., Suzuki, A., Palladium-catalyzed cross-coupling reactions of organoboron compounds. Chem. Rev. 95 (1995), 2457–2483.
7. 2 synthase-1 (mPGES-1) inhibitors using a virtual fragment growing optimization scheme. ChemMedChem 11 (2016), 612–619.
8. Schrödinger Release 2017-1, QikProp. 2017, Schrödinger, LLC, New York, NY.
9. Congreve, M., Carr, R., Murray, C., Jhoti, H., A “rule of three” for fragment-based lead discovery?. Drug Discov. Today 8 (2003), 876–877.
10. Baell, J.B., Holloway, G.A., New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays. J. Med. Chem.(53), 2010, 2719–2740.
11. Rishton, G.M., Reactive compounds and in vitro false positives in HTS. Drug Discov. Today 2 (1997), 382–384.
12. Hann, M., Hudson, B., Lewell, X., Lifely, R., Miller, L., Ramsden, N., Strategic pooling of compounds for high-throughput screening. J. Chem. Inf. Comput. Sci. 39 (1999), 897–902.
13. Schrödinger Release 2017-1, Glide. 2017, Schrödinger, LLC, New York, NY.
14. Friesner, R.A., Murphy, R.B., Repasky, M.P., Frye, L.L., Greenwood, J.R., Halgren, T.A., Sanschagrin, P.C., Mainz, D.T., Extra precision glide: docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes. J. Med. Chem. 49 (2006), 6177–6196.
15. Halgren, T.A., Murphy, R.B., Friesner, R.A., Beard, H.S., Frye, L.L., Pollard, W.T., Banks, J.L., Glide: a new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening. J. Med. Chem. 47 (2004), 1750–1759.
16. Friesner, R.A., Banks, J.L., Murphy, R.B., Halgren, T.A., Klicic, J.J., Mainz, D.T., Repasky, M.P., Knoll, E.H., Shaw, D.E., Shelley, M., Perry, J.K., Francis, P., Shenkin, P.S., Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. J. Med. Chem. 47 (2004), 1739–1749.
17. Vass, M., Keserű, M., Fragments to link. A multiple docking strategy for second site binders. Med. Chem. Commun. 4 (2013), 510–514.
18. Sándor, M., Kiss, R., Keserű, G.M., Virtual fragment docking by glide: a validation study on 190 protein-fragment complexes. J. Chem. Inf. Model 50 (2010), 1165–1172.
19. Good, A.C., Liu, J., Hirth, B., Asmussen, G., Xiang, Y., Biemann, H.-P., Bishop, K.A., Fremgen, T., Fitzgerald, M., Gladysheva, T., Jain, A., Jancsics, K., Metz, M., Papoulis, A., Skerlj, R., Stepp, J.D., Wei, R.R., Implications of promiscuous pim-1 kinase fragment inhibitor hydrophobic interactions for fragment-based drug design. J. Med. Chem. 55 (2012), 2641–2648.
20. Loving, K., Salam, N.K., Woody Sherman, Energetic analysis of fragment docking and application to structure-based pharmacophore hypothesis generation. J. Comput. Aided Mol. Des. 23 (2009), 541–554.
21. Luz, J.G., Antonysamy, S., Kuklish, S.L., Condon, B., Lee, M.R., Allison, D., Yu, X.P., Chandrasekhar, S., Backer, R., Zhang, A., Russell, M., Chang, S.S., Harvey, A., Sloan, A.V., Fisher, M.J., Crystal structures of mPGES-1 inhibitor complexes form a basis for the rational design of potent analgesic and anti-inflammatory therapeutics. J. Med. Chem. 58 (2015), 4727–4737.
22. Schiffler, M.A., Antonysamy, S., Bhattachar, S.N., Campanale, K.M., Chandrasekhar, S., Condon, B., Desai, P.V., Fisher, M.J., Groshong, C., Harvey, A., Hickey, M.J., Hughes, N.E., Jones, S.A., Kim, E.J., Kuklish, S.L., Luz, J.G., Norman, B.H., Rathmell, R.E., Rizzo, J.R., Seng, T.W., Thibodeaux, S.J., Woods, T.A., York, J.S., Yu, X.P., Discovery and characterization of 2-acylaminoimidazole microsomal prostaglandin E synthase-1 inhibitors. J. Med. Chem. 59 (2016), 194–205.
23. Partridge, K.M., Antonysamy, S., Bhattachar, S.N., Chandrasekhar, S., Fishera, M.J., Fretland, A., Gooding, K., Harvey, A., Hughes, N.E., Kuklish, S.L., Luz, J.G., Manninen, P.R., McGee, J.E., Mudra, D.R., Navarro, A., Norman, B.H., Quimby, S.J., Schiffler, M.A., Sloan, A.V., Warshawsky, A.M., Weller, J.M., York, J.S., Yu, X.-P., Discovery and characterization of [(cyclopentyl)ethyl]benzoic acid inhibitors of microsomal prostaglandin E synthase-1. Bioorg. Med. Chem. Lett. 27 (2017), 1478–1483.
24. Kuklish, S.L., Antonysamy, S., Bhattachar, S.N., Chandrasekhar, S., Fisher, M.J., Fretland, A.J., Gooding, K., Harvey, A., Hughes, N.E., Luz, J.G., Manninen, P.R., McGee, J.E., Navarro, A., Norman, B.H., Partridge, K.M., Quimby, S.J., Schiffler, M.A., Sloan, A.V., Warshawsky, A.M., York, J.S., Yu, X.-P., Characterization of 3,3-dimethyl substituted N-aryl piperidines as potent microsomal prostaglandin E synthase-1 inhibitors. Bioorg. Med. Chem. Lett. 26 (2016), 4824–4828.
25. Li, D., Howe, N., Dukkipati, A., Shah, S.T.A., Bax, B.D., Edge, C., Bridges, A., Hardwicke, P., Singh, O.M.P., Giblin, G., Pautsch, A., Pfau, R., Schnapp, G., Wang, M., Olieric, V., Caffrey, M., Crystallizing membrane proteins in the lipidic mesophase. Experience with human prostaglandin E2 synthase 1 and an evolving strategy. Cryst. Growth Des. 14 (2014), 2034–2047.
26. Di Micco, S., Spatafora, C., Cardullo, N., Riccio, R., Fischer, K., Pergola, C., Koeberle, A., Werz, O., Chalal, M., Vervandier-Fasseur, D., Tringali, C., Bifulco, G., 2,3-Dihydrobenzofuran privileged structures as new bioinspired lead compounds for the design of mPGES-1 inhibitors. Bioorg. Med. Chem. 24 (2016), 820–826.
27. Botta, A., Sirignano, E., Popolo, A., Saturnino, C., Terracciano, S., Foglia, A., Sinicropi, M.S., Longo, P., Di Micco, S., Identification of lead compounds as inhibitors of stat3: design, synthesis and bioactivity. Mol. Inf. 34 (2015), 689–697.
28. Rees, D.C., Congreve, M., Murray, C.W., Carr, R., Fragment-based lead discovery. Nat. Rev. Drug Discov. 3 (2004), 660–672.
29. Sastry, G.M., Dixon, S.L., Sherman, W., Rapid shape-based ligand alignment and virtual screening method based on atom/feature-pair similarities and volume overlap scoring. J. Chem. Inf. Model 51 (2011), 2455–2466.
30. Zhou, P., Zou, J., Tian, F., Shang, Z., Fluorine bonding–how does it work in protein-ligand interactions?. J. Chem. Inf. Model 49 (2009), 2344–2355.
31. Harder, E., Damm, W., Maple, J., Wu, C., Reboul, M., Xiang, J.Y., Wang, L., Lupyan, D., Dahlgren, M.K., Knight, J.L., Kaus, J.W., Cerutti, D., Krilov, G., Jorgensen, W.L., Abel, R., Friesner, R.A., OPLS3: a force field providing broad coverage of drug-like small molecules and proteins. J. Chem. Theory Comput. 12:1 (2016), 281–296.
32. Koeberle, A., Siemoneit, U., Bühring, U., Northoff, H., Laufer, S., Albrecht, W., Werz, O., Licofelone suppresses prostaglandin E2 formation by interference with the inducible microsomal prostaglandin E2 synthase-1. J. Pharmacol. Exp. Ther. 326:3 (2008), 975–982.
33. Capdevila, J.H., Morrow, J.D., Belosludtsev, Y.Y., Beauchamp, D.R., DuBois, R.N., Falck, J.R., The catalytic outcomes of the constitutive and the mitogen inducible isoforms of prostaglandin H2 synthase are markedly affected by glutathione and glutathione peroxidase(s). Biochemistry 34:10 (1995), 3325–3337.
34. Mitchell, J.A., Akarasereenont, P., Thiemermann, C., Flower, R.J., Vane, J.R., Selectivity of nonsteroidal antiinflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase. Proc. Natl. Acad. Sci. U. S. A. 90:24 (1993), 11693–11697.
35. Gupta, K., Selinsky, B.S., Kaub, C.J., Katz, A.K., Loll, P.J., The 2.0 Å resolution crystal structure of prostaglandin H2 synthase-1: structural insights into an unusual peroxidase. J. Mol. Biol. 335:2 (2004), 503–518.
36. Still, W.C., Tempczyk, A., Hawley, R.C., Hendrickson, T., Semianalytical treatment of solvation for molecular mechanics and dynamics. J. Am. Chem. Soc. 112 (1990), 6127–6129.
37. Schrödinger Release 2017-1, LigPrep. 2017, Schrödinger, LLC, New York, NY.
38. Orlando, B.J., Malkowski, M.G., Substrate-selective inhibition of cyclooxygeanse-2 by fenamic acid derivatives is dependent on peroxide tone. J. Biol. Chem. 291:29 (2016), 15069–15081.
39. Schrödinger Release 2017-1, Schrödinger Suite 2017-1 Protein Preparation Wizard. 2017, Epik, Schrödinger, LLC, New York, NY Impact, Schrödinger, LLC, New York, NY, 2017; Prime, Schrödinger, LLC, New York, NY, 2017.
40. Sastry, G.M., Adzhigirey, M., Day, T., Annabhimoju, R., Sherman, W., Protein and ligand preparation: parameters, protocols, and influence on virtual screening enrichments. J. Comput. Aid. Mol. Des. 27:3 (2013), 221–234.
41. Schaible, A.M., Koeberle, A., Northoff, H., Lawrenz, B., Weinigel, C., Barz, D., Werz, O., Pergola, C., High capacity for leukotriene biosynthesis in peripheral blood during pregnancy, Prostaglandins, Leukotrienes Essent. Fat. Acids 89:4 (2013), 245–255.
42. Koeberle, A., Muñoz, E., Appendino, G.B., Minassi, A., Pace, S., Rossi, A., Weinigel, C., Barz, D., Sautebin, L., Caprioglio, D., Collado, J.A., Werz, O., SAR studies on curcumin's pro-inflammatory targets: discovery of prenylated pyrazolocurcuminoids as potent and selective novel inhibitors of 5-lipoxygenase. J. Med. Chem. 57:13 (2014), 5638–5648.